|
|
 |
|
Viewing report
|
|
|
|
Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile
Datamonitor, Nov 2010, Pages: 104
Introduction
This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Chugai's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Chugai over the next six years.
Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Chugai's performance against key rivals in the prescription pharmaceutical sector
- Assess the strong sales performance of the company's monoclonal antibody (MAb) franchise, positioning Chugai as the leading Japanese MAb player
|
|
|
|
